6|19|10 Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes 8|5|09 Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis 3|24|09 Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 11|20|08
Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes
8|5|09
Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
3|24|09
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
11|20|08
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
6|9|08
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
4|2|08
Radius Completes Enrollment of Phase 2 Clinical Trial of BA058 for Osteoporosis
1|30|08
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes
9|17|07
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis / MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius
6|8|07
Radius Presents Positive Results from Phase 1B Clinical Trial of BA058 and Preclinical Study of RAD1901 at ENDO 2007
4|2|07
Radius Raises $57.5 Million in Second Private Financing Round
3|20|07
Radius Begins Phase 2 Clinical Trial of BA058 for Osteoporosis
1|2|07
Radius Appoints Nick Harvey Senior Vice President and CFO
8|7|06
Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists
6|29|06
Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs
4|12|06
Radius Appoints Louis O’Dea Senior Vice President and Chief Medical Officer
12|13|05
Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 / PTHrP Analog in Phase 1 Clinical Trials
11|12|04
Nuvios* Names Dr. Christopher Glass to Scientific Advisory Board
10|4|04
Nuvios* Names C. Richard Lyttle President and CEO
*Name changed to Radius effective December 2005
© 2005 Radius Health, Inc. | Privacy Policy | Home | Contact
300 Technology Square, Fifth Floor, Cambridge, MA 02139 Tel: (617) 551-4700 | Fax: (617) 551-4701
